| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.4 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.051 | 0.4 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.4 |